24 September 2020: Clinical Research
A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19
Zhongchao Wang 1ABCDEFG* , Dewei Zhang 2BC* , Shengming Wang 3BC* , Yanhua Jin 2BC* , Jianbo Huan 4BC* , Yue Wu 5CDF* , Cheng Xia 2CD , Zhe Li 6B , Xingshun Qi 7CF , Duanzhen Zhang 8DF , Xiumin Han 8DF , Xianyang Zhu 8DEF , Ying Qu 9ABCDEFG* , Qiguang Wang 8ACDEFG*DOI: 10.12659/MSM.926651
Med Sci Monit 2020; 26:e926651
Table 2 Main in-hospital medications of all included COVID-19 patients complicated with hypertension.
| Parameters | Overall (n=210) | ACEIs/ARBs (n=81) | Non-ACEIs/ARBs (n=129) | P value |
|---|---|---|---|---|
| Main in-hospital medications, n (%) | ||||
| Antiviral drugs | 176 (83.81) | 70 (86.42) | 106 (82.17) | 0.416 |
| Antibiotics | 75 (35.71) | 34 (41.98) | 41 (31.78) | 0.123 |
| Traditional Chinese Medicine | 192 (91.43) | 75 (92.59) | 117 (90.70) | 0.633 |
| Antidiabetic drugs | 48 (22.86) | 20 (24.69) | 28 (21.71) | 0.616 |
| Glucocorticoid | 60 (28.57) | 28 (34.57) | 32 (23.02) | 0.127 |
| Immunoglobulin | 78 (37.14) | 33 (40.74) | 45 (34.88) | 0.393 |
| ACEIs | 16 (7.62) | 16 (19.75) | 0 (0.0) | 0.000 |
| ARBs | 65 (30.95) | 65 (80.25) | 0 (0.0) | 0.000 |
| CCBs | 139 (66.19) | 49 (60.49) | 90 (69.77) | 0.167 |
| Diuretics | 18 (8.57) | 10 (12.35) | 8 (6.20) | 0.122 |
| β-blockers | 60 (28.57) | 28 (34.57) | 32 (24.81) | 0.127 |
| Nitrates | 18 (8.57) | 5 (6.17) | 13 (10.08) | 0.325 |
| Antiplatelets or anticoagulants | 64 (30.48) | 29 (35.80) | 35 (27.13) | 0.184 |
| Lipid-lowering drugs | 56 (26.67) | 25 (30.86) | 31 (24.03) | 0.276 |
| ACEIs – angiotensin-converting enzyme inhibitors; ARBs – angiotensin II receptor blockers; CCBs – calcium channel blockers. | ||||